BioSpace News Archive

Gamida Cell Ltd. today announced the presentation of data supporting the potential of omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant at the 2022 Cord Blood Connect Meeting, being held in South Beach, Florida.

Mednow Inc. will participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a distribution agreement with IPS Genomix s.a.l. (“IPS”), a medical diagnostics distributor with offices in Beirut, Lebanon and Dubai, UAE.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the appointment of Garry Nicholson as chairman of its board of directors.

Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the initiation of a global Phase 2 program of botensilimab, an Fc-enhanced anti-CTLA-4 that activates innate and adaptive immune responses.

Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced that Chief Scientific Officer Ash Jayagopal, Ph.D., and Vice President of Clinical Development Erin O’Neil, M.D., will present at the 3rd Annual Gene Therapy for Ophthalmic Disorders meeting taking place September 13-16, 2022, in Boston.

Parkinson & Movement Disorder Alliance, in partnership with Neurocrine Biosciences, a leading neuroscience-focused biopharmaceutical company committed to meeting the needs of people with complex and debilitating disorders, announced results from the Survey Assessment: Impact of OFF Time on People with Parkinson’s Disease and Their Care Partners.

Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

FSD Pharma Inc. today announces that it is presenting and participating via the on-demand session at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

Volastra Therapeutics , an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech’s 2022 “Fierce 15,” designating it as one of the most promising early-stage biotechnology companies in the industry.